ClinicalTrials.gg
RecruitingNCT07881120DISCOVERYUpdated Nov 10, 2026

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

A Phase 2/3 interventional study of Afimetoran and Placebo in Cutaneous Lupus Erythematosus (CLE) and Systematic Lupus Erythematosus, sponsored by Beeline Medicines Corporation. Recruiting at 3 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Beeline Medicines Corporation · Phase 2/3, Interventional, and Treatment

Updated Nov 10, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.

Planned enrollment
4th of 34
390 · median 46
Started
2026
with 4 others
Phase 2/3
2 of 39
1 open now
Primary completion
2030-04
later than 13 of 15 live
Registered
39th of 39
by date

Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 4th largest by planned enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 15 other live ones, and was the 39th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or without systemic lupus, whose disease has not responded to or who cannot tolerate antimalarial therapy. Participants are assigned by chance to receive afimetoran or a matching placebo capsule once daily for 24 weeks, in addition to their existing standard lupus care. Neither participants nor study staff know which treatment is given.

The study is run in two stages under a single protocol. Stage 1 compares two doses of afimetoran with placebo to select the dose. Stage 2 compares the selected afimetoran dose with placebo to confirm efficacy and safety. After the 24-week placebo-controlled period, all participants receive afimetoran for a further 28 weeks, for a total of 52 weeks of treatment. The main measures of benefit are the change in the CLASI-A skin activity score and the proportion of participants achieving a 70% improvement in that score at Week 24.

03

Conditions studied

  • Cutaneous Lupus Erythematosus (CLE)
  • Systematic Lupus Erythematosus

Keywords

  • Subacute cutaneous lupus erythematosus (SCLE)
  • Chronic cutaneous lupus erythematosus (CCLE)
  • discoid lupus erythematosus (DLE)
  • Afimetoran;
  • BLN-256;
  • BMS-986256;
  • TLR7/TLR8 antagonist
  • CLASI-A
  • antimalarial-refractory
  • Afimetoran
  • antimalarial-intolerant
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged ≥18 years (or ≥16 years where permitted).
  2. confirmed active cutaneous lupus erythematosus (CLE) with or without systemic manifestations.
  3. Active subacute and/or chronic cutaneous lupus erythematosus, including discoid lupus erythematosus.
  4. Moderate to severe skin disease activity.
  5. , intolerant, or inadequately controlled on antimalarial therapy.
  6. Willing and able to comply with study requirements.
  7. Agreement to protocol-specified requirements

Exclusion criteria

Exclusion Criteria:

  1. Severe lupus nephritis or severe neuropsychiatric SLE
  2. Drug-induced lupus
  3. Active or chronic infections, including , , , active tuberculosis, untreated latent tuberculosis, or uncontrolled congestive heart failure
  4. Significant concurrent disease other than lupus-related conditions permitted by the protocol
  5. Active or recent history of certain cancers
  6. Other dermatologic conditions that may interfere with study assessments
  7. Recent use of prohibited medications or therapies
  8. Prior treatment with afimetoran or another TLR7/TLR8 antagonist
  9. Clinically significant laboratory abnormalities or severe organ dysfunction
  10. Pregnancy or breastfeeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Afimetoran Dose 1

    Drug: Afimetoran

  • Experimental
    Afimetoran Dose 2

    Drug: Afimetoran

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Afimetoran (BLN-256) oral capsule, once daily

    Also known as: BLN-256

  • DrugPlacebo

    Placebo (capsule matched to afimetoran), once daily

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in CLASI-A total score

    Demonstrates efficacy of afimetoran vs placebo based on CLASI-A change in participants with active CLE with or without systemic manifestations

    Time frame: Baseline to Week 24

  2. Proportion of participants achieving a CLASI-70 response (≥70% decrease from baseline in CLASI-A total score)

    To demonstrate the superiority of afimetoran compared with placebo based on CLASI-70 response in participants with active CLE with or without systemic manifestations

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Participants achieving a CLASI-70 response

    Proportion of participants achieving a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) response of at least 70% (CLASI-70). Participants achieve a CLASI-70 response if they have a ≥70% decrease from baseline in CLASI-A total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.

    Time frame: Weeks 12, 16, and 24

  2. Proportion of participants achieving a CLASI-50 response

    Proportion of participants achieving a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) response of at least 50% (CLASI-50). Participants achieve a CLASI-50 response if they have a ≥50% decrease from baseline in CLASI-A total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.

    Time frame: Weeks 12, 16, and 24

  3. Proportion of Participants Achieving a CLASI-A Total Score of 0 to 3

    Proportion of participants achieving a CLASI-A total score of 0 to 3. Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity.

    Time frame: Weeks 12, 16, and 24

  4. Proportion of Participants Achieving a Cutaneous Lupus Activity-Investigator's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1

    Proportion of participants achieving a CLA-IGA-R Erythema score of 0 (clear) or 1 (almost clear). Scores range from 0 to 4, with lower scores indicating less disease activity.

    Time frame: Weeks 12, 16, and Week 24

  5. Percent Change From Baseline in CLASI-A Total Score

    Percent change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) total score. CLASI-A scores range from 0 to 70, with higher scores indicating greater cutaneous lupus disease activity. A decrease from baseline indicates improvement.

    Time frame: Weeks 12, 16, and 24

  6. Proportion of Participants Achieving a CLA-IGA-R Mucous Membrane, Edema, and Scale/Hypertrophy (OMC) Score of 0 or 1

    Proportion of participants achieving a CLA-IGA-R OMC score of 0 (clear) or 1 (almost clear). Scores range from 0 to 4, with lower scores indicating less disease activity

    Time frame: Weeks 12, 16, and Week 24

  7. Time to First CLASI Response

    Time from baseline to first achievement of a protocol-defined CLASI response, including CLASI-70 (≥70% decrease from baseline in CLASI-A total score), CLASI-50 (≥50% decrease from baseline in CLASI-A total score), or a CLASI-A total score of 0 to 3

    Time frame: Baseline through 24 weeks

  8. Change From Baseline in Cutaneous Lupus Erythematosus Quality of Life (CLE-QoL) Total Score

    Change from baseline in the Cutaneous Lupus Erythematosus Quality of Life total score. It is a 37-item patient-reported outcome measure that assesses the impact of cutaneous lupus erythematosus on quality of life across multiple domains. With higher scores indicating greater impairment in quality of life and a worse outcome.

    Time frame: Weeks 12, 16, 24, and 52

  9. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score

    Change from baseline in DLQI total score. Scores range from 0 to 30, with higher scores indicating greater impairment in quality of life.

    Time frame: Weeks 12, 16, 24, and 52

  10. Change From Baseline in Patient Global Assessment of Skin Disease Activity (PtGA-Skin Disease Activity)

    Change from baseline in PtGA-Skin Disease Activity score. The assessment uses a numeric rating scale ranging from 0 to 10. Higher scores indicate greater disease activity and worse symptoms.

    Time frame: Weeks 12, 16, 24, and 52

  11. Incidence of Serious Adverse Events (SAEs)

    Number of participants experiencing at least one serious adverse event.

    Time frame: Up to 52 Weeks

  12. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants experiencing at least one treatment-emergent adverse event.

    Time frame: Up to 52 Weeks

  13. Proportion of Participants Achieving a ≥4-Point Reduction From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Proportion of participants with SLE at baseline achieving a reduction of at least 4 points from baseline in SLEDAI-2K score without change in lupus standard-of-care therapy and/or increase in oral corticosteroid dose. SLEDAI-2K scores range from 0 to 105, with higher scores indicating greater disease activity.

    Time frame: Weeks 24 and 52

  14. Proportion of Participants With SLE at Baseline Achieving Lupus Low Disease Activity State (LLDAS)

    Proportion of participants with SLE at baseline achieving LLDAS

    Time frame: Weeks 24 and 52

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — No internal process at this time

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Apr 2030, 41 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 19, 2026
StartActual
Nov 3, 2026was Oct 2026
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
3 sites added — first site in United States. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • University Clinical Trials · San Diego, United Statesno status→Recruiting
  • Omega Research DeBary, LLC · DeBary, United Statesno status→Recruiting
  • Boeson Research MSO · Missoula, United Statesno status→Recruiting
Show 3 added (3 United States)
  • University Clinical Trials · San Diego, United States
  • Omega Research DeBary, LLC · DeBary, United States
  • Boeson Research MSO · Missoula, United States
across 2 updates, Oct 28, 2026 – Oct 29, 2026
Start date
Oct 2026→Nov 3, 2026 (actual)
Nov 10, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 28, 2026
  • DescriptionChange From Baseline in Cutaneous Lupus Erythematosus Quality of Life (CLE-QoL) Total Score: how it is measured was reworded
What changed on Oct 29, 2026
  • AddedProportion of Participants achieving a CLASI-70 responseTime frame: Weeks 12, 16, and 24
  • AddedProportion of participants achieving a CLASI-50 responseTime frame: Weeks 12, 16, and 24
  • AddedProportion of Participants Achieving a CLASI-A Total Score of 0 to 3Time frame: Weeks 12, 16, and 24
  • AddedPercent Change From Baseline in CLASI-A Total ScoreTime frame: Weeks 12, 16, and 24
  • AddedTime to First CLASI ResponseTime frame: Baseline through 24 weeks
  • RemovedProportion achieving CLASI-70 response, CLASI-50 response, and CLASI-A total score of 0-3; percent and absolute change from baseline in CLASI-A total score; time to first and sustained responseTime frame: Weeks 12, 16, and 24 (time-to-event up to Week 24)
across 2 updates, Oct 28, 2026 – Oct 29, 2026
Title
Phase 2/3 Double-Blind, Placebo-Controlled Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
Oct 28, 2026
Registered
First appeared on the registry
Oct 19, 2026
Show all 4 updates
  1. Nov 10, 2026
    Start date Oct 2026→Nov 3, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 29, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • University Clinical Trials · San Diego, United Statesno status→Recruiting
    • Omega Research DeBary, LLC · DeBary, United Statesno status→Recruiting
    • Boeson Research MSO · Missoula, United Statesno status→Recruiting
    Secondary outcomes 5 added, 1 removed
    What changed in the outcomes
    • AddedProportion of Participants achieving a CLASI-70 responseTime frame: Weeks 12, 16, and 24
    • AddedProportion of participants achieving a CLASI-50 responseTime frame: Weeks 12, 16, and 24
    • AddedProportion of Participants Achieving a CLASI-A Total Score of 0 to 3Time frame: Weeks 12, 16, and 24
    • AddedPercent Change From Baseline in CLASI-A Total ScoreTime frame: Weeks 12, 16, and 24
    • AddedTime to First CLASI ResponseTime frame: Baseline through 24 weeks
    • RemovedProportion achieving CLASI-70 response, CLASI-50 response, and CLASI-A total score of 0-3; percent and absolute change from baseline in CLASI-A total score; time to first and sustained responseTime frame: Weeks 12, 16, and 24 (time-to-event up to Week 24)
  3. Oct 28, 2026
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • University Clinical Trials · San Diego, United States
    • Omega Research DeBary, LLC · DeBary, United States
    • Boeson Research MSO · Missoula, United States
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange From Baseline in Cutaneous Lupus Erythematosus Quality of Life (CLE-QoL) Total Score: how it is measured was reworded
    Title Phase 2/3 Double-Blind, Placebo-Controlled Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
  4. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881120
Lead sponsor
Beeline Medicines Corporation
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Nov 3, 2026
Primary completion
Apr 2030 (estimated)
Completion
Apr 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Study Director
Contact
medinfo@beelinemedicines.com
1 617 885-8290
Study Director
study director · Beeline Medicines Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion